A Ludwig Cancer Research study has discovered that the metabolic decline that accompanies aging impairs the efficacy of CAR-T cell therapy, an immunotherapy in which T cells of the immune system are ...

Age-associated nicotinamide adenine dinucleotide decline drives CAR-T cell failure. Chimeric antigen receptor (CAR) T cell therapy is one of the most promising cancer treatments.

Niagen Bioscience, Inc. is headquartered in Los Angeles, CA. The company operates out of three main business segments: ...

From biohacking to ageing control & wellness monitoring, the world’s ultra-rich are going the extra mile to stay young and ...

NEW YORK - A Ludwig Cancer Research study has discovered that the metabolic decline that accompanies aging impairs the ...

In a breakthrough finding, researchers have revealed that age-related immune decline can significantly impair the ...

Age-related decline in the immune system can have a measurable impact on CAR-T cell therapy -- one of the most advanced form ...

The team used NAD-boosting compounds currently under clinical investigation for other conditions, demonstrating that this ...

CAR T cells from older individuals have lower antitumor activity due to metabolic impairment, but researchers have been able ...

As people age, their immune systems become less efficient, posing a challenge for cancer therapies that rely on harnessing immune cells.

A study by Swiss researchers highlights the challenges aging poses for CAR-T cell therapy, a groundbreaking cancer treatment.